Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.30: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 2.00; Below-average business quality.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally... Read more
Sell if holding. Engine safety override at $18.30: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 4.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 54d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — Monte Rosa Therapeutics, Inc.
Latest news
- NEWS JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31 — benzinga May 11, 2026 positive
- NEWS Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate — benzinga May 7, 2026 negative
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga May 6, 2026 neutral
- NEWS Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified — benzinga Apr 20, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.30: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $16.96. Score 4.2/10, moderate confidence.
Take-profit target: $28.13 (+54.3% upside). Prior stop was $16.96. Stop-loss: $16.96.
Quality below floor (1.4 < 4.0).
Monte Rosa Therapeutics, Inc. trades at a P/E of N/A (forward -10.0). TrendMatrix value score: 5.4/10. Verdict: Sell.
15 analysts cover GLUE with a consensus score of 4.3/5. Average price target: $32.
What does Monte Rosa Therapeutics, Inc. do?Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small...
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.